Prediagnostic use of anticoagulant treatment in patients with renal cell carcinoma: Impact on stage distribution and postoperative prognosis.

Among 5730 renal cell carcinoma patients, 21.0% were current and 11.4% former anticoagulant users.

At diagnosis, the odds of having higher stage (stage III/ IV) was slightly lower among anticoagulant users (adjusted ORs were 0.90 [95% CI 0.71-1.00] for current users and 0.85 [95% CI 0.73-0.90] for former users).

Current users had slightly higher 90-day mortality (adjusted hazard ratio [aHR] 1.10 [95% CI 0.65-1.88]), but lower one-year mortality (aHR 0.81 [95% CI 0.60-1.07]) compared with non-users.

Former users had slightly higher one-year mortality (aHR 1.12 [95% CI 0.82-1.54]).